Draig Therapeutics
Phase 2Draig is dedicated to delivering next-generation treatments for neuropsychiatric disorders through the development of highly targeted neuromodulators that redefine the existing treatment paradigm and enable people with neuropsychiatric disorders to live their best life.
Founded
2020
Focus
Small Molecules
About
Draig is dedicated to delivering next-generation treatments for neuropsychiatric disorders through the development of highly targeted neuromodulators that redefine the existing treatment paradigm and enable people with neuropsychiatric disorders to live their best life.
Funding History
3Total raised: $22.4M
Seed$3.2MUndisclosedFeb 15, 2023
Series A$15MSR OneJul 15, 2021
Seed$4.2MCambridge Innovation CapitalNov 15, 2019
Company Info
TypePrivate
Founded2020
LocationCambridge, United Kingdom
StagePhase 2
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile